AI companies attempt to improve drug development success rates through virtual clinical trials
NVS Novartis AG ADR
$140.79 -0.10%
View chart & analysis → - 1AI startup BioinvestGPT predicted in July that the clinical benefits of Del-desiran would be minimal through virtual trials.
- 2Novartis shares fell 11% last month after Del-desiran failed to meet late-stage clinical trial objectives.
- 3Novartis saw a $30 billion loss in market capitalization.
So what's the key point?
The AI company BioinvestGPT predicted in advance that a drug would have little effect. As predicted, Novartis shares fell 11% after the drug failed to meet its trial goals.
Source Reuters · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.